Mizuho raises Pulse Biosciences stock price target on trial progress
What it means
- What to watch: $PLSE had its price target revised — one analyst's number is a data point, not a thesis.
- How the stock is trading: $PLSE -0.13% in the latest session.
- Timing: It came out pre-market, so the next session was the first that could react.
Where the stock stands
$PLSE last changed hands at $53.00, -0.13% on the session, 10% below its 52-week high of $58.90 and 322% above its low of $12.56 — in the upper part of the range. Over the year it has ranged 369% from low to high: a very wide band; big swings are routine for this one, not news. These are latest-session quotes, not live prices — the live tape is on the $PLSE page.
How much coverage it is getting
Nothing else on $PLSE in the last 30 days: this is the only story Wook has filed, so there is no run to measure it against yet. 12 related stories from the same name or desk are listed beside this one.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. On Wook's supply-chain scanner, Health Care reads watch today — early signs of strain worth keeping an eye on.
What to watch next
For the receipts, the $PLSE page has the full chart, the filings and the valuation model these figures come from. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. And Wook AI, up top, will happily do the math — how far $PLSE sits from its high, or how this week's coverage stacks up.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $PLSE. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.